Temozolomide-Induced Myelodysplasia
A patient who had received temozolomide (TMZ) as a single agent in treatment of malignant glioma developed therapy-induced myelodysplasia (T-MDS). TMZ is an orally active imidazotetrazine which methylates guanine residues in DNA, ultimately causing single and double-strand DNA breaks leading to apop...
Saved in:
Main Authors: | Ethan A. Natelson, David Pyatt |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2010/760402 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog
by: Ethan A. Natelson, et al.
Published: (2013-01-01) -
Introduction to the Review Series on Myelodysplasia
by: Moshe Mittelman
Published: (2025-01-01) -
Myelodysplasia and Mast Cell Leukemia with t(9;22)
by: Kathryn J. Lago, et al.
Published: (2017-01-01) -
Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia
by: Aristides Armas, et al.
Published: (2017-01-01) -
Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials
by: Yuanyuan Chen, et al.
Published: (2025-02-01)